Efficacy and Safety of Fruquintinib Plus PD-1 Inhibitors Versus Regorafenib Plus PD-1 Inhibitors in Refractory Microsatellite Stable Metastatic Colorectal Cancer

Efficacy and Safety of Fruquintinib Plus PD-1 Inhibitors Versus Regorafenib Plus PD-1 Inhibitors in Refractory Microsatellite Stable Metastatic Colorectal Cancer

BackgroundMicrosatellite stability (MSS) or mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC) is resistant to immune checkpoint inhibitors. Studies have shown that antiangiogenic drugs combined with programmed death receptor-1 (PD-1) inhibitors can improve immunosuppression. The...

Full description

Bibliographic Details
Main Authors: Liying Sun, Shenglan Huang, Dan Li, Ye Mao, Yurou Wang, Jianbing Wu
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-10-01
Series:Frontiers in Oncology
Subjects:
colorectal cancer
immunotherapy
microsatellite stable
fruquintinib
regorafenib
PD-1
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.754881/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.754881/full

Similar Items